An article published online on April 14, 2016, in JAMA Oncology [ 1 ] proposed that “a paradigm shift to reduce overtreatment of indolent tumors” is to be created by changing the name of encapsulated follicular variant papillary thyroid carcinoma (EFVPTC) to “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” (NIFTP). This revised nomenclature essentially reclassifies these tumors from the current status as “low risk” or “very low risk” cancers to being not cancers at all. The article has been viewed some 80,000 times online and has
Justin S. Michael, Bong-Seop Lee, Miqin Zhang and John S. Yu
BBB, active targeting to tumor tissue needs to be improved.
Polymeric nanoparticles and CED
Paclitaxel (PTX), a chemotherapeutic agent, has been encapsulated in a nanoparticle (NP) composed of poly(lactide-co-glycolide) (PLGA). The encapsulation allows the toxic chemotherapeutic agent sequestered only within the NP until it gets into the tumor tissue by the EPR effect, which reduces systemic toxicity. Although the EPR effect is highly beneficial to nanotechnology, it is a passive process and only small amount of NPs can enter the GBM tissue. The polymeric NPs
Rachid Attou, Thomas Albrich, Joe Kadou, Sebastien Redant, Patrick M. Honoré and David De Bels
In spite of the introduction of this therapy, night fever peaks (38–39° Centigrade (C)) persisted. Therefore, a primary source of sepsis was actively searched. On the first instance, prostatic encapsulated abscess secondary to the traumatic manipulation was investigated. Accordingly, antibiotic treatment was switched from amoxicillin-clavulanic acid to ceftazidime.
Aerobic and anaerobic blood cultures were all negative. Continuous investigation of the sepsis source encompasses positron emission tomography scanner (pet-scan), which revealed no infection site, and